## **WAC Disclosure for Colorado Prescribers**

KALYDECO® (ivacaftor)

ORKAMBI® (lumacaftor/ivacaftor)

SYMDEKO® (tezacaftor/ivacaftor and ivacaftor)

TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)

- Colorado law requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost ("WAC") of marketed drugs when engaging in prescription drug marketing activities.
- Please refer to each product's FDA-approved label and indication for further information.
- The pricing information below represents the WAC. WAC represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers, not including prompt pay or other discounts, rebates, or reductions in price.
- The actual cost to a patient is based on several factors, including insurance coverage and potential financial or product assistance options available to them.
- Colorado law also requires manufacturers to provide the names of generic drugs in the same therapeutic class as the marketed products. There are no generic drugs in the same therapeutic class as the drugs listed below, so no such names are included in this disclosure.

| Vertex Marketed Products              | WAC Price (28-day supply) |
|---------------------------------------|---------------------------|
| KALYDECO <sup>®</sup> (all strengths) | \$26,546.00               |
| ORKAMBI <sup>®</sup> (all strengths)  | \$23,238.98               |
| SYMDEKO <sup>®</sup> (all strengths)  | \$24,883.96               |
| TRIKAFTA® (all strengths)             | \$26,546.00               |

Vertex Pharmaceuticals Incorporated is the source of this information.

Disclosed Prices Effective Date: July 2024

## **WAC Disclosure for Colorado Prescribers**

- Colorado law requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost ("WAC") of marketed drugs when engaging in prescription drug marketing activities.
- Please refer to the product's FDA-approved label and Indication for further information.
- The pricing information below represents the WAC. WAC represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers, not including prompt pay or other discounts, rebates, or reductions in price.
- The actual cost to a patient is based on several factors, including insurance coverage and potential financial or product assistance options available to them.
- Colorado law also requires manufacturers to provide the names of generic drugs in the same therapeutic class as the marketed products. There are no generic drugs in the same therapeutic class as the drugs listed below, so no such names are included in this disclosure.

## CASGEVY® (exagamglogene autotemcel)

| Vertex Marketed Products            | WAC Price      |
|-------------------------------------|----------------|
| CASGEVY® (exagamglogene autotemcel) | \$2,200,000.00 |

Vertex Pharmaceuticals Incorporated is the source of this information.

Disclosed Price Effective Date: July 2024